LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International)

Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger

By Cormac Sheridan

Wednesday, April 24, 2002

Buy Reprint

No Abstract

Leukemia Case Report Gives Gene Therapy Projects Pause For Thought

By Sharon Kingman

Wednesday, April 24, 2002

Buy Reprint

No Abstract

Apovia Raises EUR19M Privately To Fund Vaccine Development

By Douglas Merrill

Wednesday, April 24, 2002

Buy Reprint

No Abstract

BioWorld

Store

Others

BioWorld-International-2002-04-24

YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M

Faust Pharmaceuticals Obtains $2.6M To Develop CNS Drugs

Report Says EU Biotech Trails U.S. Due To Lack Of Coordination

Molecular Skincare Spun Out To Develop Skin Disease Treatments

Other News To Note

Xenova Enters Potential $63M Deal With Genentech For OX40

Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger

Leukemia Case Report Gives Gene Therapy Projects Pause For Thought

Apovia Raises EUR19M Privately To Fund Vaccine Development

Explore BioWorld.com

BioWorld

Store

Others

Login to Your Account

BioWorld

Store

Others

BioWorld-International-2002-04-24

Explore BioWorld.com

BioWorld

Store

Others